Pundkar Aditya Ganesh, Shrivastava Sandeep, Chandanwale Rohan, Jaiswal Ankit, Patel Hardik
Department of Orthopaedics, J.N. Medical College, Datta Meghe Institute of Higher Education, Wardha, Maharashtra India.
Indian J Orthop. 2024 Jun 9;58(8):1009-1015. doi: 10.1007/s43465-024-01199-z. eCollection 2024 Aug.
Biologics like growth factors, stem cells, and platelet-rich plasma show potential in stimulating cartilage regrowth and reducing inflammation. By synthesizing preclinical and clinical studies, this study offers insights into how these biologics work and their effectiveness in treating knee osteoarthritis.
Twenty-four participants with knee osteoarthritis (Kellgren - Lawrence grade II or III) were enrolled after obtaining consent. They received three doses of 2 ml intraarticular platelet-rich plasma at 1 month intervals. The clinical assessment involved the oxford knee score (OKS) and visual analogue scale (VAS) for pain on Days 0, 90, and 180. Ultrasound measured femoral and trochlear cartilage thickness pre- (Day 0) and post-PRP (Day 90-180).
Before treatment, the average pain score was 7.2 ( = 1.03). On Day 90 post-PRP, it decreased to 5 ( = 0.81), and by Day 180, it further reduced to 4.5 ( = 0.97). The initial total OKS was 33.5 ( = 1.76), which increased to 36 ( = 1.71) on Day 90 and 38.5 ( = 1.89) on Day 180. The femoral and trochlear cartilage thickness also showed improvement from baseline (0.92) to Day 90 (0.96) and Day 180 (1.01), indicating significant cartilage healing post-PRP administration.
Our study highlights the probability of PRP in treating knee OA, highlighting their ability to alleviate symptoms, enhance joint function, and promote articular cartilage regeneration.
生长因子、干细胞和富血小板血浆等生物制剂在刺激软骨再生和减轻炎症方面显示出潜力。通过综合临床前和临床研究,本研究深入探讨了这些生物制剂的作用机制及其在治疗膝关节骨关节炎中的有效性。
在获得同意后,招募了24名膝关节骨关节炎(凯尔格伦-劳伦斯分级为II级或III级)参与者。他们每隔1个月接受3剂2毫升关节内注射富血小板血浆。临床评估包括在第0天、第90天和第180天使用牛津膝关节评分(OKS)和视觉模拟评分(VAS)评估疼痛情况。超声测量了注射富血小板血浆前(第0天)和注射后(第90 - 180天)股骨和滑车软骨厚度。
治疗前平均疼痛评分为7.2(标准差 = 1.03)。在注射富血小板血浆后第90天降至5(标准差 = 0.81),到第180天进一步降至4.5(标准差 = 0.97)。初始总OKS为33.5(标准差 = 1.76),在第90天增至36(标准差 = 1.71),在第180天增至38.5(标准差 = 1.89)。股骨和滑车软骨厚度也从基线(0.92)改善到第90天(0.96)和第180天(1.01),表明注射富血小板血浆后软骨有显著愈合。
我们的研究突出了富血小板血浆治疗膝关节骨关节炎的可能性,强调了其缓解症状、增强关节功能和促进关节软骨再生的能力。